BofA analyst Derik de Bruin upgraded West Pharmaceutical to Buy from Neutral with a price target of $405, up from $390. Rising worldwide obesity rates have created huge demand for drugs to treat weight loss and Type-2 diabetes, and BofA sees GLP-1s as a meaningful near-term driver, the analyst tells investors in a research note. The firm estimates the GLP-1 opportunity for West to be 3%-8% of total sales in 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on WST: